drugset
drugset / Trial / NCT04999631

SADBE for Congenital Melanocytic Nevi

NCT04999631 ↗

Phase 0 Not yet recruiting 30 enrolled Massachusetts General Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

A study to evaluate the safety and efficacy topical squaric acid dibutylester (SADBE) for the neoadjuvant treatment of congenital melanocytic nevi (CMN).

Timeline

Start
2027-01-01
Primary completion
2030-01-01
Completion
2030-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Squaric Acid Dibutyl Ester Small molecule 0.2 % Topical

Indications

melanocytic nevus